Skip Navigation

Annals of Oncology 2007 18(9):1433-1435; doi:10.1093/annonc/mdm363
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coleman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coleman, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorials

Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1–75)

MP Coleman

Cancer Research UK Cancer Survival Group, Non-Communicable Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, UK

(E-mail: michel.coleman@lshtm.ac.uk)

The first 150 words of the full text of this article appear below.


   Introduction
 
In 2005, Sweden's famous Karolinska Institute allowed its name to become associated with the Karolinska Report, which concluded that the more cancer drugs there are on the market in a country, and the more quickly they are licensed for the market, the higher is that country's cancer survival rate [1].

The standard of evidence used in the first Karolinska Report to link cancer survival and the availability of cancer drugs was far below that used by the drug industry and licensing authorities to assess whether a drug is effective [2]. When asked "If they pushed that evidence forward to the regulatory bodies, it wouldn't be accepted?", I confidently said it wouldn't stand up in peer-reviewed publication, never mind with a licensing authority [3].

I was wrong. Karolinska Report 2 has now been published [4], no longer European but global in scope, . . . [Full Text of this Article]


   the new Karolinska report
 

   the impact of chemotherapy on cancer survival
 

   strategy
 

   summary
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?